Oncological outcomes post focal low‐dose‐rate brachytherapy in low‐intermediate risk prostate cancer

BJUI Compass 2026 Open access

Read full text
Authors: Mohammadmehdi Adhami, Jeremy Cheng, Elliot Anderson, Lloyd M. L. Smyth, Cate Davey, Thang Nguyen, Richard O'Sullivan, Andrew Ryan, Nathan Lawrentschuk, Jeremy Grummet, Andrew W. See
DOI: 10.1002/bco2.70129
Cited by: 0
References: 36

Abstract

Objectives: To prospectively evaluate oncological control, pathological progression, and its predictors following focal low-dose-rate (LDR) brachytherapy for low-intermediate risk prostate cancer (PCa). Patients and methods: LIBERATE is a prospective, multi-centre clinical registry of patients who have undergone focal LDR brachytherapy for low-intermediate risk PCa since September 2019 (ACTRN:12619001669189). Unifocal ISUP GG1 (≥10 mm in ≥1 core), GG2 (any length) or GG3 (longest core

Fields of Study & Subjects

Prostate Cancer Diagnosis and Treatment Advanced Radiotherapy Techniques Breast Cancer Treatment Studies

Publication details

Journal / source
BJUI Compass
Volume
7
Issue
2
Pages
e70129–e70129
Publication date
1 February 2026
Language
EN